Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 202…